Molcovir 200

Molnupiravir

COVID-19 in adults who do not require O₂ initiation & those at increased risk for hospitalisation or death.

800 mg every 12 hr for 5 days taken as soon as possible after diagnosis of COVID-19 & w/in 5 days of symptom onset.

May be taken with or without food: Swallow whole w/ sufficient amount of fluid. Do not open, crush or chew.

Hypersensitivity.

Hypersensitivity including severe acute intolerance (anaphylaxis). Discontinue immediately & institute drug or supportive therapy if clinically significant anaphylaxis occurs. Patients w/ active cancer excluding non-invasive cancers not associated w/ immunosuppression or significant morbidity/mortality eg, melanoma basal cell carcinoma; CKD excluding patients requiring dialysis or those w/ decrease in eGFR <30 mL/min/1.73 m²; COPD; obesity (BMI ≥30 kg/m²); severe heart conditions including CHF, CAD or cardiomyopathies; diabetes. Evaluate women of childbearing age if pregnant prior to initiating treatment. Women of childbearing age must use effective contraception during treatment & up to 4 days after receiving last dose. Males w/ female partners of childbearing potential must use effective contraception correctly & regularly. Maternal & foetal problems eg, preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease & infant death in the womb. Not recommended for use during pregnancy. Refrain from breastfeeding during treatment & until 4 days after receiving last dose. Not for use in ped patients <18 yr; may affect bone & cartilage growth. Elderly >60 yr.

Diarrhea, nausea, dizziness.

Antivirals

J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors ; Used in the systemic treatment of viral infections.

S